High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer

Pembrolizumab appears promising for patients with programmed cell death ligand-1 (PD-L1)-positive solid tumors. However, data on immunotherapy for biliary tract cancers (BTC) are limited. We aimed to investigate the predictive value of PD-L1 expression as an immunotherapeutic biomarker in BTC. Patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahn, Soomin, Lee, Jong-chan, Shin, Dong Woo, Kim, Jaihwan, Hwang, Jin-Hyeok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378166/
https://www.ncbi.nlm.nih.gov/pubmed/32704067
http://dx.doi.org/10.1038/s41598-020-69366-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7378166/
https://www.ncbi.nlm.nih.gov/pubmed/32704067
http://dx.doi.org/10.1038/s41598-020-69366-4

Ejemplares similares